SS Innovations International CEO Details Strategy to Broaden Access to Affordable Robotic Surgery
Found this article helpful?
Share it with your network and spread the knowledge!
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, is advancing its strategy to broaden access to robotic surgery through lower-cost technology, physician training, and remote surgical capabilities, according to a recent Medsider interview with founder, chairman and CEO Dr. Sudhir Srivastava.
Affordability and accessibility remain core priorities as the company expands its surgical robotics platform globally. Artificial intelligence, automation, and new robotic platforms are central to the long-term product roadmap. Telesurgery and teleproctoring have become important differentiators, allowing expert surgeons to support complex procedures remotely.
The SSi Mantra system was designed to reduce the cost of robotic surgery while supporting multiple specialties, including cardiac surgery. The company has installed more than 200 robotic systems and completed more than 11,700 robotic procedures, including over 170 telesurgeries. SS Innovations is pursuing FDA and European regulatory approvals while expanding into additional international markets.
Rather than concentrating solely on competing with existing robotic surgery platforms, Dr. Srivastava described the company's objective as expanding access to hospitals and patients that have historically been unable to adopt robotic surgery because of equipment costs and operating expenses. This approach could significantly impact the healthcare industry by making advanced surgical technology available to a broader patient population, particularly in underserved regions.
The implications of this strategy are far-reaching. For the medical device industry, SS Innovations' focus on cost reduction and remote capabilities may pressure incumbent players to lower prices or innovate faster. For healthcare providers, especially those in rural or developing areas, the ability to perform complex surgeries with lower-cost robots and remote proctoring could improve patient outcomes and reduce the need for patient travel. Investors should note the company's progress in regulatory approvals and market expansion as key indicators of future growth.
Forward-looking statements in this article involve risks and uncertainties. For full terms of use and disclaimers, refer to the InvestorBrandNetwork website. The original release is available on NewMediaWire.